Tip 2 diabetes mellituslu hastalarda plazma homosistein düzeyinin normal popülasyonla karşılaştırılması

Amaç: Preproliferatif ve proliferatif diabetik retinopatili hastalar ile retinopatisi olmayan diabetes mellitus hasta- larının plazma homosistein düzeylerinin normal popülas- yonla karşılaştırılması amaçlanmıştır. Gereç ve yöntem: Tip 2 diabet 23 hastanın plazma ho- mosistein düzeyleri ile benzer yaş grubunda, herhangi bir sistemik hastalığı ve oküler problemi olmayan 25 olgunun plazma homosistein düzeyleri karşılaştırıldı. Homosistein düzeyi yüksek performanslı sıvı kromatografi yöntemi ile ölçüldü. Bulgular: Diabetes mellituslu olgular fundus muayene- lerine göre üç gruba ayrıldı. 8 olguda diabetik retinopati bulgusu olmadığı, 8’inde preproliferatif, 7’sinde proliferatif diabetik retinopati olduğu saptandı. Plazma homosistein düzeyi diabetes mellituslu grupta (ortalama 13,30±4,03 μmol/L), kontrol grubuna göre (ortalama 11,71±3,41 μmol/L) yüksek olmakla birlikte her iki grup arasında ista- tistiksel olarak anlamlı fark bulunmadı (p>0,05). Diabetes mellituslu grup içinde ise diabetik retinopatisi olmayan grupta plazma homosistein düzeyi ortalaması 12,50±3,73 μmol/L iken, preproliferatif diabetik retinopati grubunda ortalama 12,90±2,59 μmol/L; proliferatif diabetik retinopa- tisi olan grupta ise ortalama 14,64±5,69 μmol/L düzeyinde saptandı. Ortalama plazma homosistein düzeyi retinopa- tinin ilerlemesiyle artış göstermekle birlikte bulguların is- tatistiksel analizinde bu artış anlamlı bulunmadı (p>0,05). Sonuç: İstatistiksel olarak anlamlı olmamakla birlikte plazma homosistein düzeyinin özellikle retinopati ilerle- dikçe artması plazma homosistein düzeyinin tip 2 diabe- tes mellituslu olguların takibinde kullanılabileceğini ancak daha büyük çalışma gruplarının daha kesin bilgi verebile- ceğini düşündürmektedir.

Comparison of plasma homocysteine levels in patients with type 2 diabetes mellitus with normal subjects

Objectives: To compare the plasma homocysteine levels between control group and diabetic patients with no dia- betic retinopathy, with preproliferative diabetic retinopa- thy, with proliferative diabetic retinopathy. Materials and methods: Plasma homocysteine levels of 23 diabetic patients were measured and were compared with 25 age-matched controls with no systemic problem and no ocular disease. Plasma homocysteine levels were measured using high-performance liquid chromatogra- phy. Results: Diabetic patients were divided into three groups according to their ophthalmological findings. There were 8 patients with no diabetic retinopathy, 8 patients with preproliferative diabetic retinopathy, 7 patients with pro- liferative diabetic retinopathy. Plasma homocysteine lev- els were higher in diabetic patients (13.30±4.03 μmol/L) compared to the control group (11.71±3.41 μmol/L) but no statistically significant difference was found between the two groups (p>0.05). Plasma homocysteine levels were measured 12.50±3.73 μmol/L in no diabetic retinopathy group, 12.90±2.59 μmol/L in preproliferative diabetic reti- nopathy group, 14.64±5.69 μmol/L in proliferative diabetic retinopathy group. In diabetic group, plasma homocys- teine levels increased with the increase of the severity of retinopathy but not reached statistically significance (p>0.05). Conclusion: Although no statistically significance was found, retinopathy progresses with the increase of plas- ma homocysteine levels. This can be used for the follow- up of the diabetic patients but further evaluation in large groups is needed.

PDF

___

1. Kempen JH, O’Colmain BJ, Leske MC, et al. Eye Dis- eases Prevalence Research Group: The prevalence of diabetic retinopathy among adults in the United States. Arch Ophthalmol 2004;122(4):552-63.
2. Davidson JA, Ciulla TA, McGill JB, Kles KA, Anderson PW. How the diabetic eye loses vision. Endocrine 2007;32(1):107-16.
3. Castro R, Rivera I, Blom HJ, Jakobs C, de Almeida IT. Homocysteine metabolism, hyperhomocysteinemia and vascular disease: an overview. J Inherit Metab Dis 2006;29(1):3-20.
4. Clarke R, Daly L, Robinson K, et al. Hyperhomocyşteinemia: An independent risk factor for vascular disease. N Engl J Med 1991;324(17):1149- 55.
5. Graham IM, Daly LE, Refsum HM, Robinson K, Bratt- strom LE, Ueland PM. Plasma homocysteine as a risk factor tor vascular disease. The European Concerted Action Project. JAMA 1997;277(22):1775-81.
6. Stampfer MJ, Malinow MR,Willett WC, et al. A pro- spective study of plasma homocysteine and risk of myocardiaI infarction in US physicians. JAMA 1992; 268(7): 877-81.
7. Pery I, Refsum H, Morris RW, Ebrahim SB, Ueland PM, Shaper AG. Prospective study of serum total homo- cysteine concentration and risk of stroke in middle- aged British men. Lancet 1995;346(8987):1395-8.
8. Lieberman TW, Podos SM, Hartstein J. Acute glauco- ma, ectopia lentis and omocystinuria. Am J Ophthal- mol 1966;61(2):252-5.
9. Stanger O, Weger M, Obeid R, et al. Impairment of homocysteine metabolism in patients with retinal vas- cular occlusion and nonarteritic ischemic optic neu- ropathy. Clin Chem Lab Med 2005;43(10):1020-5.
10. Wenzler EM, Rademakers AJ, Boers GH, Cruysberg JR, Webers CA, Deutman AF. Hyperhomocysteinemia in retinal artery and retinal vein occlusion. Am J Oph- thalmol 1993;115(2):162-7.
11. Coral K, Raman R, Rathi S, et al. Plasma homocysteine and total thiol content in patients with exudative age- related macular degeneration. Eye 2006;20(2):203-7.
12. Brazionis L, Rowley K Sr, Itsiopoulos C, Harper CA, O’Dea KK. Homocysteine and diabetic retinopathy. Diab Care 2008;31(1):50-6.
13. Hofmann MA, Kohl B, Zumbach MS, et al. Hyperho- mocysteinemia and endothelial dysfunction in IDDM. Diabetes Care 1998;21(5):841-8.
14. Vaccaro O, Perna AF, Mancini FP, et all. Plasma ho- mocysteine and microvascular complications in type 1 diabetes. Nutr Metab Cardiovasc Dis 2000;10(6);297- 304.
15. Kark JD, Selhub J, Bostom A, Adler B, Rosenberg IH. Plasma homocysteine and all-cause mortality in dia- bates. Lancet 1999;353(9168):1936-7.
16. Hoogeveen EK, Kostense PJ, Jakobs C, et al. Hy- perhomocysteinemia increases risk of death, espe- cially in type 2 diabetes. 5-year follow-up of the Hoorn study. Circulation 2000;101(13):1506-11.
17. Hoogeveen EK, Kostense PJ, Eysink PE, et al. Hy- perhomocysteinemia is associated with the presence of retinopathy in type 2 diabetes mellitus: the Hoorn study. Arch Intern Med 2000;160(19):2984-90.
18. Goldstein M, Leibovitch I, Yeffimov I, Gavendo S, Sela BA, Loewenstein A. Hyperhomocsteinemia in diabe- tes mellitus with and without diabetic retinopathy. Eye 2004;18(5):460-5.
19. Aydin E, Demir HD, Ozyurt H, Etikan I. Association of plasma homocysteine and macular edema in type 2 diabetes mellitus. Eur J Ophthalmol 2008;18(2):226- 32.
20. Aydemir O, Türkcüoğlu P, Güler M, et al. Plasma and vitreous homocysteine concentrations in pa- tients with proliferative diabetic retinopathy. Retina. 2008;28(5):741-3.
21. Raposo B, Rodríguez C, Martínez-Gonza ́lez J, Badi- mon L. High levels of homocysteine inhibit lysyl oxi- dase (LOX) and downregulate LOX expression in vas- cular endothelial cells. Atherosclerosis 2004;177(1):1- 8.
22. Coral K, Angayarkanni N, Gomathy N, et al. Homo- cysteine levels in the vitreous of proliferative diabetic retinopathy and rhegmatogenous retinal detachment: its modulating role on lysyl oxidase. Invest Ophthal- mol Vis Sci 2009;50(8):3607-12.
23. Kim HJ, Kim MK, Kim JU, Ha HY, Choi BY. Major de- terminants of serum homocysteine concentrations in a Korean population. J Korean Med Sci 2010;25(4):509- 16.
24. Saw SM, Yuan JM, Ong CN, et al. Genetic, dietary, and other lifestyle determinants of plasma homocys- teine concentrations in middle-aged and older Chi- nese men and women in Singapore. Am J Clin Nutr 2001;73(2):232-9.